News

AusperBio Secures $63 Million to Propel Hepatitis B Therapies

AusperBio Secures $63 Million to Propel Hepatitis B Therapies

AusperBio Secures $63 Million to Accelerate Hepatitis B Therapies

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively known as AusperBio) have announced the successful closing of their Series B2 financing round, raising an impressive $63 million. This funding signifies a strong vote of confidence from existing investors, reflecting their belief in AusperBio's innovative approach to treating chronic hepatitis B (CHB).

Investors Show Confidence in AusperBio’s Vision

The financing round was co-led by prominent organizations including Qiming Venture Partners, alongside other strategic investors such as HanKang Capital and CDH Investments. This collaboration underscores the strong interest in AusperBio's goal to develop targeted oligonucleotide therapies aimed at achieving a functional cure for CHB.

Purpose of the Financing

With the proceeds from this financing, AusperBio is set to advance its clinical development of AHB-137, the company's lead product candidate. This includes the ongoing pivotal trial and several Phase II combination studies. Additionally, the funding will facilitate the global expansion of these clinical developments, as well as the advancement of the proprietary Med-Oligo™ ASO platform, which is essential for their pipeline's growth and upcoming manufacturing partnerships.

Insights from the Leadership Team

Dr. Guofeng Cheng, the co-founder and CEO of AusperBio, expressed gratitude for the support from their investors and emphasized how this financial backing is crucial in pushing their clinical programs forward. He stated that this funding positions the company to speed up the development of AHB-137 and expand its global clinical initiatives.

Setting New Standards for Chronic Hepatitis B Treatment

Dr. Chris Yang, the co-founder and Chief Scientific Officer of AusperBio, shared insights about AHB-137, noting it as the first candidate from their Med-Oligo™ platform to reach the pivotal development phase. The encouraging data gathered so far demonstrates its potential as a mainstay therapy for CHB. He also mentioned that the financing would help advance the next generation combination therapy for this challenging condition.

Driving Forward with Advanced Solutions

AusperBio is recognized for pioneering a fresh approach to addressing chronic hepatitis B, which poses a significant public health concern worldwide. William Hu, Managing Partner of Qiming Venture Partners, stated his confidence in the AusperBio team and the transformative therapies they are developing for patients globally.

About AHB-137

AHB-137 is a novel unconjugated antisense oligonucleotide (ASO) that is being developed with AusperBio's Med-Oligo™ technology. This investigational medicine aims to provide a functional cure for chronic hepatitis B with encouraging clinical data supported by presentations at significant global conferences. Currently, AHB-137 is progressing through its Phase I and multiple Phase II trials, moving closer to a potential breakthrough in treatment for HBV.

About AusperBio

AusperBio is a biopharmaceutical company dedicated to revolutionizing treatment methodologies through oligonucleotide and targeted delivery technologies. With endeavors both in the USA and China, their mission focuses on overcoming chronic hepatitis B infection. Their Med-Oligo™ ASO platform enhances the current ASO therapeutics significantly by incorporating innovative insights into ASO design, enabling effective treatments for viral infections and other serious medical conditions.

Contact Information

For additional information, please reach out to:

Media Contact
Email: info@ausperbio.com

Investor Relations Contact:
Tel: 650-888-1756 (US)
Email: investor@ausperbio.com

Frequently Asked Questions

What is the primary focus of AusperBio?

AusperBio is focused on developing targeted therapies to achieve a functional cure for chronic hepatitis B.

How much funding did AusperBio raise in their latest financing round?

AusperBio raised $63 million in their Series B2 financing round.

What is AHB-137?

AHB-137 is a novel antisense oligonucleotide developed by AusperBio aimed at curing chronic hepatitis B.

Who are some of the investors in AusperBio?

Investors include Qiming Venture Partners, HanKang Capital, and CDH Investments.

What is the Med-Oligo™ ASO platform?

The Med-Oligo™ ASO platform is AusperBio's proprietary technology designed to enhance the effectiveness of oligonucleotide therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 154

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 197

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 101

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 227

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 16

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
BTQ Technologies Calls Investors for Key Quantum Update

Updated Category News Views 127

You know what's stirring the pot over at BTQ Technologies? A shareholder call coming up soon, and boy, it's got 'eye-opening insights' written all over it. We're talkin' Q3 financial results and, likely, a smattering of future plans on the quantum front, folks. Diving into BTQ's Quantum Vision BTQ Technologies Corp. (NASDAQ: BTQ) isn't just another tech firm banging on...

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 124

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 130

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 141

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
KeyCorp Plans Redemption of Series E Preferred Stock

Updated Category News Views 112

KeyCorp Drops a Major Redemption Bombshell Out of the blue, KeyCorp (NYSE: KEY) just tossed a curveball at investors with the announcement they’re redeeming every last one of their Series E Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock shares come December 15, 2026. This move is bound to stir the pot a bit even if you’ve been around the block a few...

Continue Reading

Top 5 Most Recently Viewed Articles

Pyramid Global Hospitality Welcomes Anthony Torres Amid Award Success

Updated Category News Views 281

Pyramid Global Hospitality Welcomes a New Leader The renowned hospitality management company, Pyramid Global Hospitality, has recently appointed Anthony Torres as its vice president of food and beverage. In this pivotal role, he will oversee the culinary vision that has underpinned the company’s award-winning reputation in the hospitality industry. Celebrating Culinary...

Continue Reading
Shamari Reid's Audiobook Earns Audie Award Nomination

Updated Category News Views 117

Shamari Reid's Audiobook Earns Audie Award Nomination Heinemann, a respected name in educational publishing, has announced that Shamari Reid's audiobook, Humans Who Teach: A Guide for Centering Love, Justice, and Liberation in Schools, has been nominated for the prestigious Audie Award in the business and personal development category. This recognition highlights the...

Continue Reading
Azazie's Summer RSVP Collection: Versatility Unleashed

Updated Category News Views 19

The Shift from Singular to Seasonal Dressing You ever get that feeling when you’re dressing for a season full of events, rather than pinning everything on just one big day? That’s what Azazie’s latest move is about, tearing up those old pages of the calendar marked just for weddings and making room for the whole shebang—every lunch, night out, and festive fling...

Continue Reading
Growing Demand for Automated Boarding Gates: Market Trends

Updated Category News Views 197

Overview of the Automatic Boarding Gates Market The automatic boarding gates market is on the rise, with expectations to reach $132.8 million by the end of the forecast period in 2032. Key factors driving this growth include an increase in air passenger traffic, ongoing technological advancements, and heightened security needs in the industry. A recent report shows that...

Continue Reading
Stride, Inc.'s Compliance Issues Under Investigation by SEC

Updated Category News Views 330

Stride, Inc. Faces Serious Investor Scrutiny Shares of Stride, Inc. (NYSE: LRN), a notable player in the educational technology sector, have seen a sharp decline in value due to recent allegations made against the company. The complaints, originating from a New Mexico school district, allege serious infractions, including fraudulent practices and conflicts of interest,...

Continue Reading